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Aminoglycosides Modified by Resistance Enzymes
Display Diminished Binding to the Bacterial
Ribosomal Aminoacyl-tRNA Site
studies on a model 27 nucleotide RNA representing the
A site of 16S rRNA revealed the significance of a nonca-
nonical A1408•A1493 base pair for paromomycin and
gentamicin binding [6–13]. The presence of the A•A mo-
tif and an adjacent bulged adenine (A1492) are critical
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Detroit, Michigan 48202 for drug binding, mainly through interactions of rings I
and II of the aminoglycosides within the major groove
of the RNA. The N1 and N3 amino groups of ring II
(2-deoxystreptamine) are conserved among aminogly-Summary
cosides, and hydrogen bond donors are generally found
at the 2 and 6 positions of ring I. Alterations of theseUnderstanding the basic principles that govern RNA
conserved or semi-conserved positions would generallybinding by aminoglycosides is important for the design
be expected to have deleterious effects on the RNAof new generations of antibiotics that do not suffer
binding properties and antibacterial activities of thefrom the known mechanisms of drug resistance. With
drugs.this goal in mind, we examined the binding of kanamy-
The emergence of antibiotic resistance has becomecin A and four derivatives (the products of enzymic
a serious problem in the treatment of bacterial infectionsturnovers of kanamycin A by aminoglycoside-modi-
over the past decade [14–16]. Bacteria have acquiredfying enzymes) to a 27 nucleotide RNA representing
the ability to modify the structures of the drugs in athe bacterial ribosomal A site. Modification of kanamy-
manner that renders them ineffective as therapeuticcin A functional groups that have been directly impli-
agents [17]. In recent years, a number of enzymes thatcated in the maintenance of specific interactions with
are able to modify aminoglycosides have been identifiedRNA led to a decrease in affinity for the target RNA.
and characterized [14]. Two of the common aminoglyco-Overall, the products of reactions catalyzed by amino-
side modifications include acetylation at the semicon-glycoside resistance enzymes exhibit diminished
served 6 amino group of ring I and phosphorylation ofbinding to the A site of bacterial 16S rRNA, which
the 3 hydroxyl group of the same ring [18]. A singlecorrelates well with a loss of antibacterial ability in
bifunctional enzyme with the ability to modify two posi-resistant organisms that harbor these enzymes.
tions in the aminoglycosides, either individually or dou-
bly, has also been identified [19, 20].
Introduction We describe in this report the application and general
use of a fluorescent A site rRNA model in the determina-
The vast majority of known antibiotics inhibit the protein tion of dissociation constants and binding modes of four
biosynthetic machinery by binding to the bacterial ribo- enzyme-modified aminoglycosides. We correlate the
some [1]. Therefore, the bacterial ribosome is a validated loss of antibacterial activities of the modified aminogly-
and important target for anti-infectives. The bacterial cosides with their resultant diminished binding affinities
ribosome has a number of drug binding sites, of which to the target rRNA. These studies not only shed light
the aminoacyl-tRNA site (“A site”) on 16S rRNA is an on the nature of these important interactions between
important one. A number of clinically useful antibiotics, aminoglycoside antibiotics and RNA, but they are also
such as aminoglycosides, are known to bind to this site. valuable tools in understanding how to retain affinity
We describe herein a system for quantitative assess- for the target bacterial rRNA in the design of structural
ment of the binding of antibiotics to the A site RNA. The variants that can resist the modifying enzymes.
system is based on the use of a fluorescent reporter
group attached to a target RNA construct, which is sen-
sitive to changes in the local environment. We describe Results and Discussion
the utility of this system in the analyses of binding by
several aminoglycoside antibiotics and four variants of A Model for the A Site of the Bacterial 16S
kanamycin A that are the products of modification by Ribosomal RNA
various resistance enzymes for these antibiotics. Puglisi and coworkers determined the solution struc-
Aminoglycoside antibiotics such as kanamycin (4,6- tures of a 27 nucleotide A site construct complexed with
disubstituted ring II subclass) and neomycin (4,5-disub- paromomycin or gentamicin [6, 7]. In both cases, the
stituted ring II subclass), which were introduced to the conserved N1 and N3 amino groups on ring II of the
clinic more than five decades ago [1], interact with the aminoglycosides make direct contacts with the rRNA
small subunit ribosomal RNA (16S rRNA) at the A site fragment at residues U1495 and G1494. Additional con-
[2–4]. Aminoglycosides contain a number of positively tacts are made through the hydrogen bonding groups
charged groups at neutral pH and a significant number on rings I and III. Similar observations were made in the
of hydrogen bond donor groups that contribute to rRNA high-resolution crystal structures of the 30S ribosomal
binding [5–8]. Recent chemical probing and structure subunit from Thermus thermophilus [21] and a eubacter-
ial ribosomal decoding-region fragment [22] complexed
with paromomycin. In this study, we have exploited the1Correspondence: csc@chem.wayne.edu
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Figure 1. The 16S rRNA A Site and Neomycin
Structures
(A) The sequence and secondary structure of
F-AS RNA, representing the A site of E. coli
ribosomal RNA, is shown. The boxed region
shows the part of RNA representing the wild-
type sequence that was used to elucidate the
interactions with paromomycin and gentami-
cin [6, 7]. The numbering of the RNA is based
on the E. coli 16S rRNA parent sequence.
(B) The structure of neomycin is shown with
the neamine portion (rings I and II) highlighted
in red.
fact that the A site RNA undergoes a local conforma- ences in the experimental conditions (e.g., temperature)
or slight influences of the RNA immobilization with biotintional change in the presence of aminoglycosides [6, 7].
Several recent studies [23–26] as well as earlier reports or fluorescein tagging. Furthermore, Wong and cowork-
ers demonstrated that higher concentrations of compet-[27] have shown that ligand-induced conformational
changes in RNA can be monitored in solution through ing ions can decrease the binding of neomycin to the
A site RNA to give dissociation constants between 25the use of attached dye molecules. A fluorescein mole-
cule attached to the 5 end of the A site construct (F-AS, and 150 nM [28], consistent with the higher Kd value
reported by Wang et al. of 132 nM [29].Figure 1A) has the ability to act as a reporter for antibiotic
binding to RNA.
Binding of Kanamycin A and Derivatives
2–5 to the A Site ModelBinding of Neomycin to the A Site Model
Binding of the well-studied aminoglycoside neomycin Kanamycin A (Figure 3) belongs to the class of 4,6-
disubstituted, 2-deoxystreptamine aminoglycosides.(Figure 1B) to F-AS was monitored by a decrease in the
fluorescence emission intensity of the attached fluores- Modifications of this drug by N-acetylation or O-phos-
phorylation are the two most prevalent mechanisms ofcein dye at 519 nm, as shown in Figure 2A. A binding
event at low concentrations (0–50 nM) of ligand was clinical resistance [14, 30, 31]. Indeed, the widespread
dissemination of the genes for 3-phosphotransferasesobserved. Fluorescence data were collected until satu-
ration was reached at 30 nM neomycin. Fitting the among pathogens has been recognized as the clin-
ical cause of the demise of kanamycin therapy [14].curve for relative fluorescence (Fr) versus free neomycin
concentration to Equation 1 (see Experimental Proce- In this study an aminoglycoside 3-phosphotransferase
(APH(3)-Ia) was employed to convert kanamycin A (1)dures and Figure 2B), which assumes a simple binding
mode and a 1:1 complex formation, gave an apparent to kanamycin A 3-phosphate (2) [32], and a second
bifunctional enzyme, aminoglycoside 2-phosphotrans-dissociation constant, Kd, of 5 nM (summarized in Table
1) for neomycin binding to F-AS. Similar results were ferase/aminoglycoside 6-acetyltransferase (APH(2)/
AAC(6)), was used to produce the corresponding singlyobtained with 4- and 20-fold lower F-AS concentrations.
Appropriate control experiments revealed that fluores- modified kanamycin A 2-phosphate (3), doubly modi-
fied kanamycin A 6-acetate 2-phosphate (4), or kana-cence quenching was not a result of photobleaching
during the titration procedure, nor from nonspecific in- mycin A 6-acetate (5) (Figure 3) [19].
Kanamycin A has become obsolete in the clinic dueteractions between fluorescein and the added drug. Ti-
trations with buffer only did not cause any changes the emergence of resistance enzymes that generate
aminoglycoside modifications such as those shown inin the fluorescence intensity of F-AS (our unpublished
data). Similarly, titrations with aminoglycoside antibiot- Figure 3 [14]. Thus, understanding the mechanism of
resistance and the effects of drug modification on RNAics (millimolar concentrations) did not lead to any
changes in the fluorescence intensity of free fluorescein binding is important for the design of more effec-
tive antibiotics. To examine whether the kanamycinor a 5-fluorescein-tagged GG dimer. Furthermore, fluo-
rescence was restored upon the addition of non-fluores- A-derived compounds could bind to the A site RNA, we
carried out titrations with F-AS and compounds 1–5. Forcein-tagged A site RNA. Our result is in good agreement
with the previously reported Kd values for neomycin the parent compound, kanamycin A (1), the fluorescence
signal of F-AS decreased initially upon drug bindingbinding that were obtained by other methods (i.e., SPR
studies gave a Kd value of 19 nM) [28, 29], further sug- until approximately 100M, then the fluorescence signal
increased and saturation was reached at a higher antibi-gesting that the fluorescein tag does not influence drug
binding. The 4-fold difference between our results and otic concentration (2 mM) (Figure 4A). The two binding
events were distinct and well separated, as indicatedthose obtained by SPR [28] may reflect possible differ-
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Figure 3. The Subclass of 4,6-Disubstituted Ring II Aminoglyco-
sides
The general structure of kanamycin A (1) is shown with functionalFigure 2. Neomycin Binding to 1 M F-AS RNA in Buffer A at 37C
groups that are modified in red (R1-R3). Derivatives 2–5 are phosphor-(A) Fluorescence changes associated with neomycin binding to
ylated or acetylated at specific positions (R1-R3). The structure ofF-AS are shown. Fluorescence emission spectra of 1 M annealed
tobramycin is shown for comparison with differences in ring I high-
F-AS before (uppermost curve) and after (lower curves) addition of
lighted in blue.
0.1–50 nM neomycin. The emission maximum at 519 nm is dimin-
ished upon drug binding. The excitation wavelength was 490 nm.
The data were collected through 100% saturation. exhibited simple binding behavior (1:1 complex), and
(B) A representative binding isotherm of the relative fluorescence the data fit well to Equation 1 (Figure 4B). The low-affinity
intensity (Fr) as a function of total neomycin concentration is shown.
event was characterized by cooperative behavior, asThe solid line represents the fit of the data to Equation 1 (R2 
determined by a non-linear Scatchard plot (our unpub-0.958).
lished data) and a Hill plot that gave a non-unity Hill
constant, n, of 1.9 (Figure 4C). The high-concentration
by the change in fluorescence signal from quenching to data fit best to Equation 4 (See Experimental procedures
enhancement; therefore, each transition was fit indepen- and Figure 4D), which assumes a more complex binding
dently. Compound 1 exhibited a first binding event with mode (in this case a 2:1 stoichiometry of drug:RNA).
a Kd value of 1.1  0.1 M and a second binding event Interestingly, electrospray ionization mass spectrom-
with a Kd value of 510  10 M. The high-affinity event etry studies revealed that the structurally related com-
pound tobramycin displays similar binding behavior to
the A site RNA (Figure 3) [33]. Both 1:1 and 2:1 stoichi-
Table 1. Dissociation Constants of Aminoglycoside Antibiotics ometries of drug:RNA were observed at low and high
and Kanamycin A Derivatives for the Bacterial A Site RNA
tobramycin concentrations, respectively. The first site
aminoglycoside Kd (M) na was attributed to specific interactions mediated by elec-
trostatic, hydrogen bonding, and stacking interactionsneomycin 0.005  0.002
at the A site bulged residue, whereas the second binding1b 1.1  0.1
2 1300  100 2.2 mode was probably governed by nonspecific electro-
3 2000  100 static interactions.
4 1700  100 2.3 As drug binds to RNA and the RNA undergoes a con-
5 600  20 2.6
formational change, the orientation or relative position-
a Average number of interacting sites. ing of the 5 fluorescein tag on the RNA will be altered.
b A second binding event was observed with this compound (Kd,2  Therefore, fluorescence polarization, or anisotropy, can
510  10 M; n  1.9).
also be used to determine the dissociation constants
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Figure 4. Compound 1 Binding to 1 M F-AS RNA in Buffer A at 37C
(A) A plot of the corrected fluorescence at 519 nm as a function of added compound 1 is shown.
(B) A representative binding isotherm of relative fluorescence intensity (Fr) (circles) as a function of total compound 1 concentration (0.1–60
M) is shown with a fit to Equation 1 (R2  0.988). The relative anisotropy (Ar) plot is shown for comparison (triangles) (R2  0.845).
(C) A Hill plot for compound 1 at high concentrations (0.2–2.5 mM) was obtained with Equation 3.
(D) Fr (circles) was plotted as a function of total compound 1 concentration (0.2–2.5 mM) and fit to Equation 4 (cooperative binding) (R2 
0.990). The Ar plot is shown for comparison (triangles) (R2  0.966). The error bars in C and D represent the standard deviation from two
separate titration experiments.
[34, 35]. Fluorescence anisotropy measurements gave tions of the drug were added to F-AS. Of the four modi-
fied compounds, only 3 exhibited simple bindingresults similar to those of the fluorescence-quenching
assay. Fitting the relative anisotropy values (Figures 4B behavior (i.e., no cooperativity). The binding of deriva-
tives 2, 4, and 5 was cooperative, and each displayedand 4D) for the high- and low-affinity binding modes
gave Kd values of 0.5  0.2 M (1:1 stoichiometry) and a nonlinear Scatchard plot (data not shown) and non-
unity Hill constants. The Hill plots are shown in Figure720  33 M (2:1 stoichiometry), respectively.
Titrations of a fluorescein-tagged human analog (18S) 5B. The Fr-versus-drug-concentration plots in Figure 5C
were fit to Equation 1 for derivative 3 or Equation 4 forof the 16S A site RNA (sequence 5-F-GGCGUCG1408CU
ACUUCGGUAA1491AAGUCGCC-3, where F  fluores- compounds 2, 4, and 5. The Kd values that were obtained
from these fits are reported in Table 1. The changes incein and sequence differences between the 16S and
18S RNAs are underlined) with kanamycin A revealed binding free energies (G values) for compounds 2–5
relative to compound 1 (Gobs of 1  Gobs of 2–5)relatively poor binding (Kd  100 M) (our unpublished
data). These results demonstrate the importance of resi- are 4.3, 4.6, 4.5, and 3.8 kcal/mol, respectively.
The nonlinear Scatchard plots for three (2, 4, and 5)dues such as A1408 and/or G1491 for kanamycin A
binding to the A site RNA. In addition, we have examined of the six compounds (and 1 at high concentration) ex-
amined in this study were suggestive of cooperativethe influence of ionic strength on the binding of kanamy-
cin A to the A site RNA. Adding higher concentrations binding modes. In these cases, a Hill-type model was
used to obtain the Kd and n values. The non-unity Hillof NaCl (up to 1 M) or increasing the pH from 7.4 to 7.8
leads to a 4- to 7-fold reduction of both specific and constants for 2, 4, and 5, as well as 1 at high concentra-
tion, are not unusual for this class of drugs. Severalnonspecific binding (our unpublished data), consistent
with previous studies [28]. groups reported that certain 4,6-linked aminoglycosides
do not always form 1:1 complexes with the A site RNATitrations of F-AS with kanamycin A derivatives 2–5
led to an increase in fluorescence in every case (Figure construct [28, 33]. Furthermore, the high number of
charged groups on these molecules might lead to multi-5A). For each derivative examined, no change in fluores-
cence of F-AS was observed until millimolar concentra- ple binding sites on the RNA because of a combination
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of attractive and repulsive electrostatic interactions. Al-
ternatively, as a result of both RNA and drug flexibility,
we may be observing different conformers of drug-RNA
complexes. The proposal of such dynamic interactions
is not unreasonable given that the target rRNA is a bio-
logically active molecule that takes part in numerous
macromolecular binding events.
Previous studies revealed that rings I and II of paromo-
mycin and gentamicin are critical for specific recognition
within the A site RNA binding pocket [6, 7, 21, 22]. In
the present study, comparisons of binding affinities for
the kanamycin derivatives reveals that the presence of
specific amino and hydroxyl groups is indeed important
for A site RNA recognition. Comparison of neomycin
and paromomycin binding to the A site RNA reveals a
10-fold enhancement in binding when a hydroxyl group
is replaced by an amino group at the 6 position of ring
I [28, 29]. Phosphorylation of the 3-hydroxyl group of
ring I on kanamycin A has a much more dramatic effect
on its binding to the A site RNA. An identical group
(OH) on paromomycin’s 3 position makes backbone
contacts in the paromomycin-RNA complex [6, 7, 22].
Thus, it is not surprising that a 	1000-fold-diminished
binding affinity for F-AS is observed when 1 is converted
to 2.
Ring III of the 4,6-linked kanamycin A likely makes
important contributions to the binding affinity, although
the contacts will be different from ring III of the 4,5-linked
compounds neomycin and paromomycin because of
different positioning (see Figures 1 and 3 for a compari-
son of the structures). The apparent dissociation con-
stant of neamine, which comprises rings I and II of neo-
mycin (Figure 1B), with A site RNA constructs is between
10 and 24 M [36, 37], compared to a Kd of 1.1 M for
kanamycin A. Ring III of gentamicin, which is structurally
similar to kanamycin A, makes additional sequence-
specific contacts with the A site RNA when it is com-
pared to paromomycin [6, 7]. Specifically, the 2 hy-
droxyl group on gentamicin, which is also found on
kanamycin A, is within hydrogen bonding distance of
G1405 (O6) and U1406 (O4) [7]. Thus, 2000- and 1700-
fold-diminished binding affinities for 2-phosphorylated
derivatives 3 and 4, respectively, are consistent with a
disruption of these important RNA-ligand contacts and
are probably due to electrostatic repulsions between
the derivatives and the RNA backbone. Similarly, disrup-
tion of the hydrogen bonding contacts between the
6-amino group and the A site RNA will be severely
compromised upon acetylation at this site (derivatives
4 and 5). As reported in Table 1, derivative 5 shows a
Figure 5. Compounds 2–5 Binding to 1 M F-AS RNA in Buffer A 600-fold-diminished binding affinity compared to that
at 37C
of 1. Taken together, our results suggest that modifica-
(A) Plots of the corrected fluorescence at 519 nm as a function of
tion of functional groups that most likely contact A siteadded compound are shown (2, closed circles; 3, squares; 4, trian-
residues will lead to a loss of the specific binding modegles; 5, open circles).
observed at low concentrations of kanamycin A,(B) Hill plots for compounds 2, 4, and 5 were obtained with Equa-
tion 3. whereas nonspecific binding modes with one or more
(C) Plots of Fr as a function of total compound are shown. Data for sites of interaction will dominate for derivatives 2–5.
compounds 2, 4, and 5 were fit to Equation 4 (cooperative binding).
Data for compound 3 were fit to Equation 1 (1:1 binding). The error
bars in B and C represent the standard deviation from two separate
Computer Modelingtitration experiments, except for 5.
Figure 6 shows the energy-minimized structure of kana-
mycin A (1) bound in the A site of rRNA template. This
compound occupies the pocket that is formed by A1492
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Figure 6. Stereo View of the Computational Model for the Complex between the A Site RNA Template and Kanamycin A
The lowest-energy conformation of the fluorescein tag is shown in ball-and-stick representation, and a portion of the binding site for kanamycin
A (color-coded ball-and-stick representation: C, white; N, blue; O, red) is shown as a green Connolly surface on the A site RNA (violet capped-
stick representation).
and the A1408•A1493 motif, as was observed with paro- Anisotropy experiments are also consistent with the
modeling studies in which the fluorescein becomes situ-momycin and gentamicin [6, 7]. In the uncomplexed
RNA, the fluorescein tag does not contact the RNA and ated closer to the RNA surface in the presence of antibi-
otics. As kanamycin A binds to F-AS, fluorescence an-points toward the solution with free rotation. After the
drug is bound, the region spanning the binding site for isotropy increases (the anisotropy value, r, is 0.045 in
the absence of drug and 0.076 at 2.5 mM kanamycinkanamycin A was accessible to various conformations
of the fluorescein tag appended at the 5 terminus. In A), indicating that the movement of the fluorescein tag
is more constrained in the drug-RNA complex. Fittingthe analysis of 1,132 conformations of the fluorescein
tag with kanamycin A present, approximately 50% of of the relative anisotropy values for the high- and low-
affinity binding modes is shown in Figures 4B and 4D.the conformations that were closer to the kanamycin
binding site showed lower energy than the remainder.
The lowest-energy conformation brings the fluorescein Antibiotic Activities of Modified Aminoglycosides
The minimum inhibitory concentration (MIC) of kanamy-tag close to the kanamycin A binding site and, in fact,
an overlay of all the conformations shows that the best cin A is 4 g/ml for E. coli JM109, but is elevated
by 	500-fold (2048 g/ml) in E. coli JM109(pSF815A),low-energy conformations capped the binding site of
kanamycin A on the A site RNA template. This observa- which expresses the bifunctional enzyme APH(2)/
AAC(6) [19]. Similarly, the MIC levels are elevated 250-tion indicates the likelihood of direct interactions be-
tween the aminoglycoside ligand bound in the A site fold in E. coli strains that express the aminoglycoside
3-phosphotransferases APH(3)-Ia and APH(3)-IIa (S.of the RNA template and the fluorescein tag at the 5
terminus following drug binding, suggesting a mecha- Vakulenko and S.M., unpublished data). Thus, a loss in
antibacterial activities associated with these modifiednism for the observed changes in fluorescence intensity
of the attached dye molecule. Differences in fluores- aminoglycoside antibiotics is consistent with a loss in
their RNA binding abilities. One possible reason for thecence intensities between the aminoglycoside-F-AS
complexes reflect variations in the drug binding modes. more dramatic loss in RNA binding upon modification
(1000- to 2000-fold reduction in binding) as comparedThe fluorescence quenching or enhancement mecha-
nism probably depends on the manner in which the dye to smaller differences in MIC values (250- to 512-fold)
is that the in vitro experiments were conducted withmolecule interacts near the surface of the drug binding
site, which will vary with aminoglycoside antibiotic fully modified compounds, whereas the compounds are
likely not to be 100% modified in the cellular environ-structure and binding orientation.
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ment [19]. Furthermore, MIC is a more complex expres- acetylation of specific functional groups on the amino-
glycosides. The goal of this work was to test the hy-sion of interactions of the drug with living bacteria, and
its direct comparison to dissociation constants of pothesis that such modifications of aminoglycoside
functional groups by natural resistance enzymes willaminoglycosides with the A site RNA should be made
with caution. Nonetheless, a clear trend is observed cause these antibiotics to have unfavorable interac-
tions with their natural biological target, the bacterialbetween the reduced RNA binding abilities of the modi-
fied antibiotics and their attenuated antimicrobial activ- A site from 16S rRNA, because of unfavorable electro-
static or van der Waals interactions. We have isolatedity in vivo.
four kanamycin A derivatives that are the products of
natural resistance enzymes and quantitatively demon-Conclusions
strated that they do in fact have reduced affinity forThe fluorescein-tagged 27 nucleotide RNA (F-AS) used
the bacterial ribosomal A site RNA. The 600- to 2000-in this study was the same sequence of RNA that was
fold reduction in binding affinities of the phosphory-used previously for NMR and chemical probing [6–13],
lated or acetylated aminoglycosides correlates wellmass-spectrometric [38], and surface plasmon reso-
with their diminished antibacterial activities. These re-nance (SPR) [28] studies; therefore, direct comparisons
sults demonstrate that the natural resistance enzymescan be made between the results described here and
modify specific functional groups on the aminoglyco-results for other aminoglycosides described elsewhere.
side antibiotics that are critical for making contactsIn the case of SPR studies, the 27 nucleotide RNA was
with the target RNA.tagged with biotin at the 5 end, which had no apparent
influence on the binding of aminoglycosides [28]. In our Experimental Procedures
studies a 6 carbon linker attached to fluorescein resides
at the same location on the 5 terminus. The fluorescein General
Neomycin sulfate (85% neomycin B,
15% neomycin C) and kana-tag is within 15 A˚ of linear distance to the aminoglyco-
mycin sulfate (kanamycin A, 5% kanamycin B) were purchasedside binding site, with little restriction on its motion.
from Sigma (St. Louis, Missouri).The low anisotropy of fluorescein is indicative of a high
rotational freedom, as was demonstrated previously
Isolation of Turnover Products of Kanamycin A
with 5-carboxyfluorescein-tagged RNA [39]. Upon drug- Compounds 2–5 were prepared by slight modifications of literature
induced RNA bending, however, the tag becomes posi- procedures [19, 32]. E. coli JM109(pSF815A) or JM83(pTZ18u) was
grown in 6 liters of Terrific Broth up to the late logarithmic phase,tioned closer to the binding site, as determined by com-
then cells were harvested by centrifugation. The cell pellet (32 gputer modeling and simulations, and has less rotational
wet cell paste) was resuspended in 100 ml buffer (50 mM HEPESfreedom. These changes in the fluorescein position lead
[pH 7.5], supplemented with 0.2 mM dithiothreitol, and 1 mM phenyl-to subsequent changes in the fluorescence intensity
methylsulfonyl fluoride), lysed by ultrasonication, and centrifuged.
(vide infra). The resulting supernatant was treated with 1 g streptomycin sulfate
The present report describes the ability of the fluores- and centrifuged at 80,000 g for 1 hr. For the removal of small mole-
cules (such as ATP and coenzyme A), the supernatant was dialyzedcein-tagged A site RNA of the bacterial ribosome to
against 10 mM HEPES (pH 7.5) supplemented with 1 mM dithio-bind modified aminoglycosides. The utility of the system
threitol.described herein for quantitative screening of antibiotics
The large-scale aminoglycoside phosphorylation procedure forhas been demonstrated for several aminoglycoside anti-
production of 2 or 3 was according to a modification of the method
biotics that are known to bind to the A site of the ribo- of Siregar et al. [32]. The phosphorylation reaction mixture consisted
some. Furthermore, we have shown for the first time in of the appropriate dialysate, 11 mM magnesium chloride, 22 mM
potassium chloride, and 200 mM HEPES at pH 7.5 in a total volumea quantitative manner that modified aminoglycosides,
of 250 ml. The reaction was started by the addition of 100 mgthe products of the reactions catalyzed by the resistance
kanamycin A, 40.6 mg phosphoenol pyruvate, 31.5 units of pyruvateenzymes, suffer from attenuated binding ability to the
kinase, and 0.51 g ATP, and the mixture was incubated at 37C forA site of 16S rRNA, which correlates well with the loss
12 hr. Subsequently, the reaction mixture was put in a boiling water
of antibacterial ability in resistant organisms that harbor bath for 10 min. The mixture was centrifuged at 3200 g for 15 min.
these enzymes. Major efforts are currently underway in The supernatant was concentrated in vacuo, then was lyophilized.
The residue was taken up in 200 ml methanol and centrifuged (3200a number of laboratories to develop antibiotics that
g for 15 min). The precipitate was washed with methanol and wasavoid the resistance mechanisms [36, 40–44]. A key to
suspended in a mixture of 10 ml water, 10 ml ethyl acetate, and 10success in these endeavors will be the identification of
ml methanol, then centrifuged at 3200 g for 15 min. This step wasvalidated targets for antibiotics and the ability to assess
repeated once. The collected pellet was resuspended in 15 ml water,
ligand binding to the site in a convenient and rapid and the insoluble materials were discarded after centrifugation (3200
manner. Thus, future efforts in this area will include the g for 15 min). The supernatant was loaded onto a CG-50 column
(NH4 salt, 20 cm  1 cm). The column was washed with 500 mldevelopment of more sensitive fluorophores within the
water, followed by elution with a linear gradient of NH4OH (0 toRNA to detect drug binding and immobilization of target
2%, 500 ml) in water. Fractions that gave positive results with theRNAs for multiple rounds of screening.
ninhydrin test were pooled and concentrated in vacuo to dryness.
The phosphorylated kanamycin A was pure, as determined by spec-
troscopic characterizations that matched previous results.Significance
For acetylation of kanamycin A to produce 5, the reaction was
set up for a biphasic acetyl coenzyme A recycling method, as de-The high toxicity and emergence of antibiotic resis-
scribed by Ouyang and coworkers [45]. Kanamycin A (100 mg) was
tance has limited the usefulness of the aminoglycoside dissolved in 200 mM HEPES buffer (pH 7.5), supplemented with 1
class of antibacterials. One prevalent mechanism of mM dithiothreitol in a total volume of 50 ml. A 4 mg portion of
coenzyme A was dissolved in the kanamycin A solution. A 2 mgresistance involves enzymatic phosphorylation or
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portion of 4-dimethylaminopyridine (DMAP) was dissolved in 5 ml The Hill constant n was also used to determine Kd with Equation 4.
toluene, and the two solutions were combined to form two phases,
Fr  [Lt]n/([Lt]n  K nd) (4)which were stirred. A 0.5 ml portion of the enzyme dialysate, pre-
pared as described above, was added to the aqueous layer, and
the mixture was gently stirred at 37C. Finally, acetic anhydride (250
Fluorescence Anisotropy Measurements
l) was added very slowly into the organic layer. Additional portions
Fluorescence anisotropy (r) was determined from Equation 5, in
of kanamycin A (100 mg), and enzyme dialysate (1 ml) were added
which I is the measured fluorescence intensity with polarizers verti-
at 2 and 4 hr of the reaction. The reaction was then stopped after
cally (v) or horizontally (h) oriented. The first letter refers to the
6 hr by boiling the solution in a water bath for 10 min. The reaction
excitation polarizer, and the second refers to the emission polarizer.
product was isolated as described for the phosphorylated product.
The grating factor, G, is defined by the ratio Ihv/Ihh [34, 35].All reactions were monitored by tlc (EtOH:MeOH:HOAc:H2O,
5:5:4.5:4.5). r  (Ivv  GIvh)/(Ivv  2GIvh) (5)
The Kd values were determined by plotting Ar (relative anisotropy)Preparation of F-AS RNA
against the total ligand concentration, [Lt], where Ar is the fractionA 5-fluorescein-labeled A site model, F-AS (5-F-GGCGUCACAC
of r due to the bound species. Ar (r0,corr  ri,corr)/(r0,corr  rF,corr), whereCUUCGGGUGAAGUCGCC-3), was synthesized by via standard
r0,corr, ri,corr, and rF,corr are the r values at the initial point (all free),silyl phosphoramidite chemistry with reagents from Glen Research
at point i in the titration, or at the final titration point (all bound),(Sterling, Virginia). The human analog RNA (5-F-GGCGUCGCUA
respectively.CUUCGGUAAAAGUCGCC-3) was obtained from Dharmacon Re-
search (Lafayette, Colorado). The RNAs were purified by electropho-
resis on denaturing (8 M urea) 15% polyacrylamide gels, followed Molecular Modeling
by electroelution with 1 TBE (90 mM Tris-HCl, 90 mM boric acid, The NMR structure of the A site RNA-paromomycin complex [6] was
and 2.5 mM Na2EDTA [pH 8.3]) in an Amicon centrilutor and Centri- obtained from the Research Collaboratory for Structural Bioinfor-
con 3 units (Amicon). The F-AS RNA and human analog RNA were matics Protein Data Bank, and paromomycin was replaced with
stored at 20C in 10 mM HEPES (pH 7.4). RNA concentrations kanamycin A (1). First, the common rings I and II in paromomycin,
were determined spectrophotometrically with molar extinction coef- and kanamycin A were retained in their NMR conformations, and
ficients of 253,300 M1·cm1 and 258,100 M1·cm1 for F-AS and the remainder of the structure was adjusted to that of kanamycin
the human analog, respectively. For renaturing, the RNAs (150 A. The negative charges on the A site RNA-paromomycin complex
M) were placed in a water bath at 20C, heated to 85C for 1 min, were neutralized by the addition of 22 Na ions by the use of
then slowly cooled back to 20C over a 2 hr period. “addIons” utility in Amber 5.0 suite of programs [47, 48]. The entire
complex was solvated in a rectangular box of TIP3 waters (10 A˚
Fluorescence Measurements thickness) and was energy minimized for 10,000 iterations with the
Fluorescence experiments were performed on a Spex Fluoromax Amber 5.0 package. The coordinates of the complex were extracted,
luminescence spectrometer. The RNA solutions were prepared as and the fluorescein tag was built at the 5 end of the A site template,
1 M F-AS in buffer A (10 mM HEPES [pH 7.4], 150 mM NaCl, and linking it to guanosine. The 5-fluorescein tag was energy minimized
3 mM Na2EDTA). Fluorescence emission spectra were obtained with with the Tripos force field with Gasteiger charges, as implemented
an excitation wavelength of 490 nm, with a band pass of 2.9 nm (0.7 in Sybyl [49]. A systematic search was performed with all the torsions
mm slit width) over the range of em 500–600 nm. All measurements in the linker between the 5-terminal guanosine and the fluorescein
were taken at 37C. Samples were incubated in a temperature- tag, C4-C5 and C5-O5 torsions on the 5-guanosine (a total of
controlled cuvette holder in the Fluoromax for 2 min before fluores- 10 torsion angles). The increment for each torsion angle was 60,
cence intensities were measured. Aliquots of the antibiotic were and energies of all the conformations were evaluated. A set of 1,132
added sequentially, and 2 min of equilibration time were allowed conformations that satisfied the van der Waals criterion were kept,
before each fluorescence measurement. and 105,988 conformations that did not satisfy this criterion in the
Fluorescence intensities were corrected for volume changes ac- search process were rejected. The energies of 1,132 conformations
cording to the following equation: Fi,corr  Fi,obs Vi/V0, where Fi,corr is were analyzed with respect to the conformation of the fluores-
the corrected intensity for point i of the titration, Fi,obs is the measured cein tag.
intensity at point i, Vi is the volume after the ith addition, and V0 is
the initial volume (typically 350 l). Acknowledgments
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